Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis.

[1]  J. Macdonald,et al.  Methotrexate for induction of remission in ulcerative colitis. , 2014, The Cochrane database of systematic reviews.

[2]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[3]  H. Hjortswang,et al.  6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  B. Gridelli,et al.  Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. , 2009, Journal of hepatology.

[5]  J. Sanderson,et al.  Further experience with the use of 6‐thioguanine in patients with Crohn's disease , 2008, Inflammatory bowel diseases.

[6]  E. Bloemena,et al.  Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  J. Westerga,et al.  Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: Prevalence of nodular regenerative hyperplasia , 2008, Scandinavian journal of gastroenterology.

[8]  C. Mulder,et al.  Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism , 2007, The American Journal of Gastroenterology.

[9]  R. Stockbrügger,et al.  Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  S. Schoenberg,et al.  Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques , 2007, European Radiology.

[11]  C. O'Morain,et al.  Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease , 2007, Scandinavian Journal of Gastroenterology.

[12]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[13]  S. Schoenberg,et al.  Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. , 2006, European journal of gastroenterology & hepatology.

[14]  W. Petritsch,et al.  6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party , 2006, Digestion.

[15]  M. Schwab,et al.  A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. , 2005, Scandinavian journal of gastroenterology.

[16]  C. Mulder,et al.  Nodular regenerative hyperplasia and thiopurines: The case for level‐dependent toxicity , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  Wolfgang Schima,et al.  A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. , 2005, Journal of hepatology.

[18]  Thomas R. Walker,et al.  6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2004, Journal of pediatric gastroenterology and nutrition.

[19]  J. Belaiche,et al.  Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine , 2003, Alimentary pharmacology & therapeutics.

[20]  S. Targan,et al.  Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine , 2003, American Journal of Gastroenterology.

[21]  M. Schwab,et al.  6‐Thioguanine — efficacy and safety in chronic active Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[22]  V. Armstrong,et al.  Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. , 2003, Clinical chemistry.

[23]  C. Mulder,et al.  6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment , 2003, European journal of gastroenterology & hepatology.

[24]  S. Targan,et al.  An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine Therapy , 2001, Inflammatory bowel diseases.

[25]  R. Boulieu,et al.  Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.

[26]  R. Weinshilboum,et al.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. , 1995, British journal of clinical pharmacology.

[27]  L. Lennard,et al.  High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. , 1992, Journal of chromatography.

[28]  I. Wanless.  micronodular transpormation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules , 1990, Hepatology.

[29]  G. Lichtenstein.  6-Thioguanine Associated Nodular Regenerative Hyperplasia in Patients With Inflammatory Bowel Disease May Induce Portal Hypertension , 2008 .